Amyotrophic Lateral Sclerosis Treatment Market

The global amyotrophic lateral sclerosis treatment market size was USD 719.2 Mn in 2022 and is likely to reach USD 1094.4 Mn by 2031, expanding at a CAGR of 5% during 2023–2031. The market growth is attributed to the increasing awareness about ALS, the growing geriatric population, and the rising incidence rate.

Amyotrophic lateral sclerosis (ALS) disease is also known as Lou Gehrig's disease. It is a progressive neurodegenerative disorder that damages nerve cells present in the central nervous system and responsible for controlling the voluntary muscles. There are some common symptoms such as weakness as a result of a reduction in the arms or legs muscle size, muscle twitching, and stiff muscles.

Get Free Sample Report

Around 50% of the total people suffering from amyotrophic lateral sclerosis might lose the capability to speak, swallow, walk, breathe, and use their hands. As stated by the National Institute of Neurological Disorders and Stroke (NINDS), ALS patients often die within 3-5 years of failure of respiratory. Sporadic and familial are two types of ALS disease. The sporadic is the most common type and holds around 90% of all cases in the U.S. Familial type of ALS is hereditary, in which there is about a 50% of chance genetic mutation inheritance and gradually disorder is developed.

In 30-40% of familial ALS patients, the defect is usually found in the C9ORF72 gene. Frontotemporal dementia (FTD) condition is generated due to a mutation in the C9ORF72 gene, this condition is developed with ALS as comorbidity referred to as ALS-FTD. There is no permanent cure for amyotrophic lateral sclerosis disease.

There are some treatments such as stem cell therapies and medications for slowing down the disease progression, management of the symptoms, and preventing unnecessary complications. Changing lifestyles results in an increased risk of developing the disorder, which makes a demand for targeted treatment options and novel therapeutic approaches.

Amyotrophic Lateral Sclerosis Treatment Market Dynamics

The global amyotrophic lateral sclerosis treatment market report has up-to-date insights that help in formulating a strategic roadmap about the estimated market scenario and performance during 2023 to 2031.

Get Free Sample Report

Market Trends, Drivers, Restraints, and Opportunities

• The Growing number of patients affected by ALS is a key factor driving the market growth over the forecast period.

• An increase in the launch of novel medicines, growing expenditure on healthcare, and well-developed healthcare infrastructure is anticipated to propel the market growth.

• An increase in strategic collaborations of research institutes and key companies for ALS treatment development, a sedentary lifestyle, and a rising risk of developing ALS is estimated to fuel the growth of the market.

• The high cost of treatment and lack of awareness about the disease among people are major factors that can hamper the growth of the ALS treatment market in the coming years.

• The low availability of treatment and the lower prevalence rate is expected to impede the market growth over the forecast period.

• Rising government initiatives for R&D of rare disease and approvals from the Food and Drug Administration (FDA) generates various opportunities for companies that are expected to fuel the growth of the market.

Scope of Amyotrophic Lateral Sclerosis Treatment Market Report

The global amyotrophic lateral sclerosis treatment market research report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.

Amyotrophic Lateral Sclerosis Treatment Market Segment Insights

Based on treatment, the amyotrophic lateral sclerosis treatment market is segmented into medication, stem cell transplant, and others. The medication segment is expected to represent a key share of the market in the coming years. Only two drugs are approved for ALS treatment, Rilutek (riluzole), and Radicava (edaravone). The Nuedexta (dextromethorphan/quinidine) drug is approved by FDA for pseudobulbar affect treatment, comorbidity of ALS.

The stem cell transplant segment is anticipated to expand at a rapid pace during the forecast period owing to the growing demand for advanced treatment and a new approach. Various initiatives are taken by government authoritative bodies and the Collaborative ALS Drug Discovery Initiative (CADDI) for the rapid development of novel drugs and treatments which is projected to increase the number of clinical trials and introduction of pipeline drugs in coming years.

Get Free Sample Report

On the basis of distribution channel, the market is divided into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment is expected to hold a key share of the market during the forecast period. The need for multiple times visits and stays during ALS treatment is driving the segment growth. A large number of patients prefer hospital pharmacies and retail pharmacies. This is attributed to quick and easy access to various drugs and adequate products offered by these distribution channels.

Other distribution channels in ALS treatment markets such as clinics, diagnostics laboratories, and online pharmacies. Online pharmacies are also growing owing to the increasing popularity of e-commerce channels which offers multiple options including in-depth information about drugs.

In terms of region, the global amyotrophic lateral sclerosis treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to the huge demand for ALS drugs, high healthcare expenditure, established healthcare infrastructure, and favorable reimbursement policies. As per published data in the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report, in 2015 around 16,500 ALS were found in the U.S.

Asia Pacific is expected to exhibit a rapid growth rate in the coming years. In this region, the industry is witnessing a rising generation of revenue from riluzole generic manufacturers, majorly in emerging countries such as India and China. Increasing investment in R&D, promising initiatives by the government and manufacturers, and plenty of unexplored opportunities are some major factors fuelling the market growth.

Get Free Sample Report

Segments

The global amyotrophic lateral sclerosis treatment market has been segmented on the basis of

Treatment

• Medication
• Stem Cell Transplant
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

Region

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Amylyx Pharmaceuticals, Inc.
• Mitsubishi Chemical Group Corporation.
• Otsuka Pharmaceutical Co., Ltd.
• BrainStorm Cell Limited.
• Biogen
• CORESTEM, Inc
• AB Science
• F. Hoffmann-La Roche Ltd
• Biohaven, Ltd.
• Sun Pharmaceutical Industries Ltd.
• Ionis Pharmaceuticals 

Competitive Landscape

Key players competing in the amyotrophic lateral sclerosis treatment market are Amylyx Pharmaceuticals, Inc.; Mitsubishi Chemical Group Corporation.; Otsuka Pharmaceutical Co., Ltd.; BrainStorm Cell Limited.; Biogen; CORESTEM, Inc; AB Science; F. Hoffmann-La Roche Ltd; Biohaven, Ltd.; Sun Pharmaceutical Industries Ltd.; and Ionis Pharmaceuticals

These companies adopted development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide.

• In June 2022, Amylyx Pharmaceuticals, Inc. announced that Health Canada has approved ALBRIOZA (also known as AMX0035). This ALBRIOZA is used for the treatment of amyotrophic lateral sclerosis.